[
    [
        {
            "time": "",
            "original_text": "[增持评级]医药生物行业周报：27.8倍的估值 或许是左侧布局的起点",
            "features": {
                "keywords": [
                    "医药生物",
                    "估值",
                    "左侧布局",
                    "增持评级"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[增持评级]医药生物行业周报：27.8倍的估值 可能是左侧布局的起点",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]